Trending...
- RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
- Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
- Exeter Smiles Encourages Families to Start Teen Braces This Summer
WEXFORD, Pa., Oct. 24, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has recently announced an expansion of its license agreement with Deverra Therapeutics Inc. This move will allow Coeptis to broaden the potential applications of its allogeneic natural killer (NK) cell technology in the treatment of viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.
The agreement, which was initially secured in August 2023, granted Coeptis exclusive rights to key assets from Deverra including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets align with Coeptis' mission to develop treatments for targeting cancer, autoimmune and infectious diseases.
With this revised agreement, Coeptis will now have the ability to expand its field of use in the event of pandemic-related and emergency situations. This includes utilizing unmodified NK cells as a treatment for illnesses and injuries arising from a pandemic or act of terror or war, such as Acute Radiation Sickness (ARS). It also allows for the production and storage of unmodified NK cells in advance to prepare for future health crises.
More on The PennZone
Dave Mehalick, President and CEO of Coeptis Therapeutics expressed his excitement about this expansion stating that it "broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic."
Coeptis Therapeutics Holdings, Inc., along with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The company's product portfolio includes assets licensed from Deverra Therapeutics, an allogeneic cellular immunotherapy platform, and DVX201, a clinical-stage unmodified natural killer cell therapy technology. They are also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.
More on The PennZone
Coeptis' business model is centered around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. Their focus is on expanding their product rights and offerings, particularly in the areas of cancer and infectious diseases. The company is headquartered in Wexford, PA.
It is important to note that this news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, and assumptions that may cause actual results to differ materially from those projected. Coeptis urges readers to carefully review all cautionary statements regarding these forward-looking statements before making any investment decisions.
For more information on Coeptis Therapeutics Holdings, Inc., please visit their website at https://coeptistx.com/.
The agreement, which was initially secured in August 2023, granted Coeptis exclusive rights to key assets from Deverra including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets align with Coeptis' mission to develop treatments for targeting cancer, autoimmune and infectious diseases.
With this revised agreement, Coeptis will now have the ability to expand its field of use in the event of pandemic-related and emergency situations. This includes utilizing unmodified NK cells as a treatment for illnesses and injuries arising from a pandemic or act of terror or war, such as Acute Radiation Sickness (ARS). It also allows for the production and storage of unmodified NK cells in advance to prepare for future health crises.
More on The PennZone
- Landmark Construction Expands Glass, Glazing, and Commercial Remodeling Services Across Los Angeles County and Surrounding Areas
- Imagen Golf Announces Strategic Partnership with The Back Nine of Yardley to Deliver World-Class Indoor Golf Instruction
- Jazzin' On Ridge Returns for Its 6th Annual Celebration of Music, Culture, and Community
- ENTOUCH Named Top 100 Inspiring Workplaces in North America for Third Consecutive Year
- Rebecca L. Francis Receives Pennsylvania's Most Influential Leaders Award
Dave Mehalick, President and CEO of Coeptis Therapeutics expressed his excitement about this expansion stating that it "broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic."
Coeptis Therapeutics Holdings, Inc., along with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The company's product portfolio includes assets licensed from Deverra Therapeutics, an allogeneic cellular immunotherapy platform, and DVX201, a clinical-stage unmodified natural killer cell therapy technology. They are also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.
More on The PennZone
- Pulse Wave is where moments become movements
- Michigan's Plane Crash Data Points Away from Big Airports
- 2iG Solutions Launches MGA Insight, Bringing AI-Powered Business Intelligence to Managing General Agents
- A Better Way to Find a Real Estate Agent Is Coming Soon
- Talentica Software Earns a Place Among India's Top 100 Great Mid-size Workplaces 2026
Coeptis' business model is centered around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. Their focus is on expanding their product rights and offerings, particularly in the areas of cancer and infectious diseases. The company is headquartered in Wexford, PA.
It is important to note that this news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, and assumptions that may cause actual results to differ materially from those projected. Coeptis urges readers to carefully review all cautionary statements regarding these forward-looking statements before making any investment decisions.
For more information on Coeptis Therapeutics Holdings, Inc., please visit their website at https://coeptistx.com/.
Filed Under: Business
0 Comments
Latest on The PennZone
- Lady Liberty Is Coming Home: Historic WWII A-26 Invader Begins Her Final Journey to the Tulsa Air & Space Museum
- The Lashe Announces Limited-Time Sale on Professional Premade Fan Lash Extension Trays
- PropAccount.com Adds Prediction Markets to Its Multi-Asset Prop Firm Platform
- ToyLookup.com Launches AI-Powered Platform to Help Collectors Identify Vintage and Modern Toys
- Rising star Hip-Hop and R&B Force Della Drops Highly Anticipated New Single, "Throw It"
- UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
- From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
- Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
- June Employment Report Reveals Hidden Weakness Beneath Lower Unemployment
- Exeter Smiles Encourages Families to Start Teen Braces This Summer
- The Hue Society Expands Roster for the 2026 Wine and Culture Fest
- Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
- Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
- Fig Lehigh Valley Celebrates 50th Edition With Summer Launch Party at the Americus Hotel
- Make America French Again Launches National Campaign
- RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
- New Children's Book Teaches Kids the Lesson Its Author Spent a Career Learning: Your Worth Doesn't Need Permission
- Proper Sky Named to the 2026 MSP 501
- 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
- Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area